MAXCYTE INC
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
MXCT$1.30+3.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Assets · · · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $46,506 | | $11,065 | ||
| Short-term investments, at amortized cost | | 121,782 | | 216,275 | ||
| Accounts receivable, net | | 5,778 | | 11,175 | ||
| Accounts receivable - TIA (Note 8) | | | — | | | 1,912 |
| Inventory | | 12,229 | | 8,581 | ||
| Prepaid expenses and other current assets | | 3,899 | | 3,258 | ||
| Total current assets | | 190,194 | | 252,266 | ||
| | | | | | | |
| Investments, non-current, at amortized cost | | | 42,938 | | | — |
| Property and equipment, net | | | 23,513 | | 23,725 | |
| Right-of-use asset - operating leases | | | 11,241 | | 9,853 | |
| Other assets | | 388 | | 809 | ||
| Total assets | | $268,274 | | $286,653 | ||
| | | | | | | |
| Liabilities and stockholders’ equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $743 | | $292 | ||
| Accrued expenses and other | | 11,269 | | 8,265 | ||
| Operating lease liability, current | | 774 | | 157 | ||
| Deferred revenue, current portion | | 5,069 | | 6,713 | ||
| Total current liabilities | | 17,855 | | 15,427 | ||
| | | | | | | |
| Operating lease liability, net of current portion | | 17,969 | | 15,938 | ||
| Other liabilities | | 283 | | 1,320 | ||
| Total liabilities | | 36,107 | | 32,685 | ||
| | | | | | | |
| Commitments and contingencies (Note 8) | | | ||||
| Stockholders’ equity | | | ||||
| Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at December 31, 2023 and December 31, 2022 | | | — | | | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized, 103,961,670 and 102,397,913 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | | | 1,040 | | | 1,024 |
| Additional paid-in capital | | 406,925 | | 390,819 | ||
| Accumulated deficit | | (175,798) | | (137,875) | ||
| Total stockholders’ equity | | 232,167 | | 253,968 | ||
| Total liabilities and stockholders’ equity | | $268,274 | | $286,653 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.